IL2 and neoplasm: RCC was classified as an “immunogenic” tumor based on the following characteristics: spontaneous regression of the tumor, high levels of T cell infiltration in the tumor, and reactivity to immunotherapy such as interleukin-2 (IL-2) and interferon alpha (IFN-α) [36].